Le Lézard
Classified in: Health, Covid-19 virus
Subject: MRR

Global $8.1 Billion Hospital Acquired Infection Control Markets to 2028: Consumables Dominated the Market and Accounted for the Largest Share of 47% in 2020

DUBLIN, Aug. 4, 2021 /PRNewswire/ -- The "Hospital Acquired Infection Control Market Size, Share & Trends Analysis Report by Type (Equipment, Services, Consumables), by End User (Hospitals & ICUs, Ambulatory Surgical & Diagnostic Centers), by Region and Segment Forecasts, 2021-2028" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global hospital acquired infection control market size is anticipated to reach USD 8.1 billion by 2028 and is expected to expand at a CAGR of 4.9% from 2021 to 2028.

The key factors driving the market growth include the rising incidence of Hospital Acquired Infections (HAIs), supportive government initiatives and the COVID-19 pandemic. The COVID-19 pandemic has emerged as a major catalyst for the market as it led to increased awareness and concern over HAIs. The demand for infection control equipment and consumables also stemmed from the need to stop the spread of COVID-19.

Governments and regulatory bodies prescribed several policies and guidelines to prevent cross-contamination and safeguard public health. To prevent nosocomial infections in healthcare facilities, infection control standards were implemented such as triage strategy and provision and proper distribution of equipment, in addition to standard precautions such as hand washing and use of personal protective equipment. In particular, the pandemic resulted in a surge in demand for consumables such as PPE, masks and disinfectants.

The CDC, of the U.S. Department of Health and Human Services, provides an extensive library of guidelines on basic infection prevention and control, antibiotic resistance, device-associated infections, procedure-associated infections and disease / organism-specific to promote the control of HAIs. In the wake of the pandemic, the CDC added COVID-19 infection control guidelines to its digital library.

Growing initiatives by market players also contribute to the growth of the market. These initiatives include strategic partnerships, mergers and acquisitions and product development.

In February 2021, for instance, Getinge expanded its partnership with XPO Logistics under which the latter will provide warehousing and transport services from the Netherlands to the EMEA region for the company's infection control business unit.

In December 2020, Xenex launched LightStrike 6 as part of its patented lineup of pathogen-eliminating robots. The robots produce high-intensity broad-spectrum UV light and can also deactivate the COVID-19 virus in 2 minutes.

Hospital Acquired Infection Control Market Report Highlights

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary
2.1 Hospital Acquired Infection Control Market Summary

Chapter 3 Hospital Acquired Infection Control Market Variables, Trends & Scope
3.1 Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Penetration & Growth Prospect Mapping, 2020
3.3 Hospital Acquired Infection Control Market Dynamics
3.3.1 Market Driver Analysis
3.3.2 Market Restraint Analysis
3.3.3. Market Challenge Analysis
3.3.4. Market Opportunity Analysis
3.4 Hospital Acquired Infection Control Market Analysis Tools: Porters
3.5 Hospital Acquired Infection Control Industry Analysis - PEST (Political & Legal, Economic, and Technological)
3.6. Regulatory Landscape
3.7. Prevalence of Hospital Acquired Infections

Chapter 4 COVID-19 Impact Analysis
4.1 COVID-19 Prevalence Analysis
4.2. Regulatory requirements/changes due to COVID-19
4.3. Strategies implemented by companies

Chapter 5 Hospital Acquired Infection Control Market: Segment Analysis, By Type, 2016 - 2028 (USD Million)
5.1 Type Market Share Analysis, 2020 & 2028
5.2 Hospital Acquired Infection Control market, by Type, 2016 to 2028
5.3 Equipment
5.3.1 Equipment market, 2016 - 2028 (USD Million)
5.3.2 Sterilization Equipment Sterilization Equipment market, 2016 - 2028 (USD Million) Heat Sterilization Equipment Heat Sterilization Equipment market, 2016 - 2028 (USD Million) Moist Heat Sterilization Dry Heat Sterilization Low Temperature Sterilization Radiation Sterilization
5.3.3 Disinfection Equipment
5.4 Services
5.5 Consumables
5.5.1 Consumables market, 2016 - 2028 (USD Million)
5.5.2. Disinfectants
5.5.3. Sterilization consumables
5.5.4. Others (waste disposal, PPE)

Chapter 6 Hospital Acquired Infection Control Market: Segment Analysis, By End User, 2016 - 2028 (USD Million)
6.1 End-user Market Share Analysis, 2020 & 2028
6.2 Hospital Acquired Infection Control market, by End User, 2016 to 2028
6.3 Hospitals and Intensive Care Units (ICUs)
6.4 Ambulatory Surgical and Diagnostic Centers
6.5 Others (Nursing Homes and Maternity Centers)

Chapter 7 Hospital Acquired Infection Control Market: Regional Market Analysis 2016 - 2028 (USD Million)
7.1 Regional Market Share Analysis, 2020 & 2028
7.2 Regional Market Snapshot
7.3 Market Size, & Forecasts, and Trend Analysis, 2016 to 2028

Chapter 8 Hospital Acquired Infection Control Market - Competitive Analysis
8.1 Market Participant Categorization
8.1.1. Company Market Position Analysis
8.1.2. Synergy Analysis: Major Deals & Strategic Alliances
8.1.3. Market Leaders
8.1.4. Innovators
8.2. List of Key Companies

Chapter 9 Hospital Acquired Infection Control Market - Company Profiles

For more information about this report visit https://www.researchandmarkets.com/r/racph1

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

These press releases may also interest you

at 22:12
Boan Biotech, a subsidiary of Luye Pharma Group, will orally present the pre-clinical data of its proprietary CD3+ T-cell engager platform and CEA/CD3 bispecific antibody at World Bispecific Summit 2021. The annual World Bispecific Summit aiming to...

at 21:26
Tech Innovation Global Incorporated's President Alicia Carroll and companies in collaboration with organizations and countries https://www.corporatevision-news.com/issue-5-2021/ are producing a documentary video in global operations during the...

at 20:33
Summary Product: Glucagon (DIN 02243297, lot D239382A, expiry May 10, 2022) Issue: Eli Lilly Canada Inc. is recalling one lot of Glucagon, following a complaint that a vial from this lot was found to be in liquid form instead of powder form....

at 12:15
Invitae , a leading medical genetics company, today presented research demonstrating that genetic findings informed clinical management changes that led to improved seizure control and outcomes in the majority of epilepsy patients with actionable...

at 11:49
Eli Lilly Canada is voluntarily recalling lot (D239382A) of GLUCAGON (Glucagon for Injection, 1 mg per vial; Diluent for Glucagon, 1 mL syringe), to the retail level. This recall is based on a single patient level product complaint report that a vial...

at 09:00
Today, IMV, part of Science and Medicine Group, the leading market research and business intelligence provider to the laboratory diagnostic industry, announced the category winners of the 2021 IMV ServiceTraktm awards in clinical analyzers....

News published on 4 august 2021 at 13:30 and distributed by: